Press release
Acute Graft Versus Host Disease Treatment Market Foreseen to Grow Exponentially by 2031
According to the report, the global acute graft versus host disease (GvHD) treatment market was valued at US$ 263 Mn in 2020 and is projected to expand at a CAGR of 8.6% from 2021 to 2031. The rise in focus on introducing novel effective therapeutics to address the unmet medical needs is anticipated to drive the global acute graft versus host disease (GvHD) treatment market from 2021 to 2031.
Read Report Overview - https://www.transparencymarketresearch.com/acute-graft-versus-host-disease-gvhd-treatment-market.html
North America is expected to account for significant share of the global acute graft versus host disease (GvHD) treatment market during the forecast period. The growth of the acute graft versus host disease (GvHD) treatment market in the region can be attributed to the presence of key players and rise in access to health care due to well-established healthcare infrastructure.
The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031. Emerging approached for mesenchymal stem cells (MSCs) to treat acute graft versus host disease (GvHD) in Japan is projected to boost the growth of market in the region.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82607
Focus on Research & Development to Propel Market
The development of innovative and effective health products for humans has increased in the past few decades. Key players focus on introduction of new drugs in the market. The research-based pharmaceutical industry can play a critical role in restoring growth and ensuring future competitiveness in an advancing global economy. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market. For instance, in July 2021, Equillium, Inc. announced the completion of an end-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) for use of itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD).
Corticosteroids to Dominate Global Market
In terms of drug class, the global acute graft versus host disease (GvHD) treatment market has been classified into corticosteroids, immunosuppressive agents, biological therapy, kinase inhibitors, monoclonal antibody, mesenchymal stem cell (MSC), and others. First-line use of corticosteroids in the treatment of GvHD is likely to boost the growth of segment.
Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82607
Intravenous Segment to Expand at High Growth Rate
Based on route of administration, the global acute graft versus host disease (GvHD) treatment market has been categorized into oral, topical, and intravenous. Increase in usage and launch of new injectable drugs for treatment of acute graft versus host disease are projected to augment the segment during the forecast period.
Retail Pharmacies to Account for Major Share of Global Market
In terms of distribution channel, the global acute graft versus host disease (GvHD) treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The increase in the number of different doses and medications for the treatment of acute GvHD is anticipated to drive the retail pharmacies segment.
Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=82607
Competition Landscape of Acute Graft Versus Host Disease (GvHD) Treatment Market
The report provides profiles of leading players operating in the global acute graft versus host disease (GvHD) treatment market. These include Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd, Equillium, Inc., Cynata Therapeutics Limited, MaaT Pharma, Incyte Corporation, Xenikos B.V., Merck & Co. (OncoImmune, Inc.), medac GmbH, and CSL Limited.
More Trending Reports by Transparency Market Research -
Placental Stem Cell Therapy Market: https://www.prnewswire.co.uk/news-releases/placental-stem-cell-therapy-market-to-surpass-us-4-4-bn-by-2030-underpinned-by-enormous-r-amp-d-in-cellular-therapies-and-regenerative-medicine-finds-tmr-study-862182963.html
Fluorine-18 Market: https://www.prnewswire.co.uk/news-releases/fluorine-18-market-to-exceed-us-3-bn-by-2030-surge-in-use-of-pet-ct-scan-in-oncology-spurs-demand-for-fdgs-notes-study-by-tmr-865401243.html
Contact Us
Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Graft Versus Host Disease Treatment Market Foreseen to Grow Exponentially by 2031 here
News-ID: 2567533 • Views: …
More Releases from Transparency Market Research
Hydrolyzed Vegetable Protein Market to Reach US$ 5,110.8 Mn by 2035, Driven by R …
The global hydrolyzed vegetable protein (HVP) market was valued at US$ 2,343.6 Mn in 2024 and is projected to reach US$ 5,110.8 Mn by 2035, expanding at a CAGR of 7.3% from 2025 to 2035. Market growth is primarily driven by the rising global demand for plant-based proteins and the rapid expansion of the food processing and convenience foods sector.
Access key findings and insights from our Report in this sample…
Automotive ECU Market to Reach USD 158.9 Billion by 2036 as Vehicles Become More …
The Automotive Electronics Control Unit (ECU) Market has emerged as a pivotal component of the global automotive industry, driven by increasing electronics content in vehicles and the transition toward connected, autonomous, and electrified transportation. Automotive ECUs are critical electronic modules that control various subsystems within vehicles - from engine performance and safety to infotainment and powertrain optimization. As vehicles evolve from purely mechanical machines to sophisticated electronic platforms, demand for…
Automotive Thermal Management System Market Poised to Reach USD 173.8 Billion by …
The global automotive thermal management system market is entering a high-growth phase, fueled by the rapid electrification of vehicles, stricter emission norms, and rising expectations for vehicle safety, comfort, and efficiency. Valued at US$ 82.6 billion in 2025, the market is projected to nearly double and reach US$ 173.8 billion by 2036, expanding at a robust CAGR of 6.8% from 2026 to 2036.
Thermal management has become a mission-critical function in…
Thermal-Management Exterior Coatings for High-Altitude Aircraft Market to be Wor …
The global Thermal-Management Exterior Coatings for High-Altitude Aircraft Market was valued at US$ 1.8 Bn in 2025 and is projected to reach US$ 9.8 Bn by 2036, expanding at a robust CAGR of 17.5% during the forecast period from 2026 to 2036.
Review critical insights and findings from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86920
This strong growth trajectory reflects the rising importance of advanced exterior coating technologies that ensure aircraft performance, safety,…
More Releases for GvHD
Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022
Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100…
Graft Versus Host Disease (GvHD) Market Expected to Expand at a Steady 2022-2028 …
Coherent Market Insights have added a new research study on Title Graft Versus Host Disease (GvHD) Market, Global Outlook and Forecast 2022-2028 with detailed information & Key Players Such as Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd. The Study provides in-depth comprehensive analysis includes Clear Market definitions, classifications, manufacturing processes, cost structures, development policies and plans. The…
Graft Versus Host Disease GvHD Treatment Market Investment Research Report 2016- …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain…
Graft Versus Host Disease GvHD Treatment Market Revenue and Value Chain 2016-202 …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain…
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.
Graft-versus-host disease (GVHD) is a complication that can occur after…
Graft Versus Host Disease (GvHD) Market - Global Industry Analysis 2024
During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a…
